Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies

Yoshiaki Nishimura, Tatsuhiko Igarashi, Nancy Haigwood, Reza Sadjadpour, Ron J. Plishka, Alicia Buckler-White, Riri Shibata, Malcolm A. Martin

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

We previously reported that high-titered neutralizing antibodies directed against the human immunodeficiency virus type 1 (HIV-1) envelope can block the establishment of a simian immunodeficiency virus (SIV)/HIV chimeric virus (SHIV) infection in two monkeys following passive transfer (R. Shibata et al., Nat. Med. 5:204-210, 1999). In the present study, increasing amounts of neutralizing immunoglobulin G (IgG) were administered to 15 pig-tailed macaques in order to obtain a statistically valid protective neutralization endpoint titer in plasma. Using an in vitro assay which measures complete neutralization of the challenge SHIV, we correlated the titers of neutralizing antibodies in plasma at the time of virus inoculation (which ranged from 1:3 to 1:123) with the establishment of infection in virus-challenged animals. Ten of 15 monkeys in the present experiment were virus free as a result of neutralizing IgG administration as monitored by DNA PCR (peripheral blood mononuclear cells and lymph node cells), RNA PCR (plasma), virus isolation, and the transfer of lymph node cell suspensions (108 cells) plus 8 ml of whole blood from protected animals to naïve macaques. The titer of neutralizing antibodies in the plasma calculated to protect 99% of virus-challenged monkeys was 1:38.

Original languageEnglish (US)
Pages (from-to)2123-2130
Number of pages8
JournalJournal of Virology
Volume76
Issue number5
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Simian Immunodeficiency Virus
Human immunodeficiency virus
Neutralizing Antibodies
neutralizing antibodies
neutralization
HIV
Viruses
viruses
Haplorhini
monkeys
Macaca
Virus Diseases
immunoglobulin G
Immunoglobulin G
Lymph Nodes
lymph nodes
Polymerase Chain Reaction
Macaca nemestrina
Simian immunodeficiency virus
Viral Load

ASJC Scopus subject areas

  • Immunology

Cite this

Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. / Nishimura, Yoshiaki; Igarashi, Tatsuhiko; Haigwood, Nancy; Sadjadpour, Reza; Plishka, Ron J.; Buckler-White, Alicia; Shibata, Riri; Martin, Malcolm A.

In: Journal of Virology, Vol. 76, No. 5, 2002, p. 2123-2130.

Research output: Contribution to journalArticle

Nishimura, Yoshiaki ; Igarashi, Tatsuhiko ; Haigwood, Nancy ; Sadjadpour, Reza ; Plishka, Ron J. ; Buckler-White, Alicia ; Shibata, Riri ; Martin, Malcolm A. / Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. In: Journal of Virology. 2002 ; Vol. 76, No. 5. pp. 2123-2130.
@article{1f7bdc1a91394e6aa075b1c56aaee850,
title = "Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies",
abstract = "We previously reported that high-titered neutralizing antibodies directed against the human immunodeficiency virus type 1 (HIV-1) envelope can block the establishment of a simian immunodeficiency virus (SIV)/HIV chimeric virus (SHIV) infection in two monkeys following passive transfer (R. Shibata et al., Nat. Med. 5:204-210, 1999). In the present study, increasing amounts of neutralizing immunoglobulin G (IgG) were administered to 15 pig-tailed macaques in order to obtain a statistically valid protective neutralization endpoint titer in plasma. Using an in vitro assay which measures complete neutralization of the challenge SHIV, we correlated the titers of neutralizing antibodies in plasma at the time of virus inoculation (which ranged from 1:3 to 1:123) with the establishment of infection in virus-challenged animals. Ten of 15 monkeys in the present experiment were virus free as a result of neutralizing IgG administration as monitored by DNA PCR (peripheral blood mononuclear cells and lymph node cells), RNA PCR (plasma), virus isolation, and the transfer of lymph node cell suspensions (108 cells) plus 8 ml of whole blood from protected animals to na{\"i}ve macaques. The titer of neutralizing antibodies in the plasma calculated to protect 99{\%} of virus-challenged monkeys was 1:38.",
author = "Yoshiaki Nishimura and Tatsuhiko Igarashi and Nancy Haigwood and Reza Sadjadpour and Plishka, {Ron J.} and Alicia Buckler-White and Riri Shibata and Martin, {Malcolm A.}",
year = "2002",
doi = "10.1128/jvi.76.5.2123-2130.2002",
language = "English (US)",
volume = "76",
pages = "2123--2130",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies

AU - Nishimura, Yoshiaki

AU - Igarashi, Tatsuhiko

AU - Haigwood, Nancy

AU - Sadjadpour, Reza

AU - Plishka, Ron J.

AU - Buckler-White, Alicia

AU - Shibata, Riri

AU - Martin, Malcolm A.

PY - 2002

Y1 - 2002

N2 - We previously reported that high-titered neutralizing antibodies directed against the human immunodeficiency virus type 1 (HIV-1) envelope can block the establishment of a simian immunodeficiency virus (SIV)/HIV chimeric virus (SHIV) infection in two monkeys following passive transfer (R. Shibata et al., Nat. Med. 5:204-210, 1999). In the present study, increasing amounts of neutralizing immunoglobulin G (IgG) were administered to 15 pig-tailed macaques in order to obtain a statistically valid protective neutralization endpoint titer in plasma. Using an in vitro assay which measures complete neutralization of the challenge SHIV, we correlated the titers of neutralizing antibodies in plasma at the time of virus inoculation (which ranged from 1:3 to 1:123) with the establishment of infection in virus-challenged animals. Ten of 15 monkeys in the present experiment were virus free as a result of neutralizing IgG administration as monitored by DNA PCR (peripheral blood mononuclear cells and lymph node cells), RNA PCR (plasma), virus isolation, and the transfer of lymph node cell suspensions (108 cells) plus 8 ml of whole blood from protected animals to naïve macaques. The titer of neutralizing antibodies in the plasma calculated to protect 99% of virus-challenged monkeys was 1:38.

AB - We previously reported that high-titered neutralizing antibodies directed against the human immunodeficiency virus type 1 (HIV-1) envelope can block the establishment of a simian immunodeficiency virus (SIV)/HIV chimeric virus (SHIV) infection in two monkeys following passive transfer (R. Shibata et al., Nat. Med. 5:204-210, 1999). In the present study, increasing amounts of neutralizing immunoglobulin G (IgG) were administered to 15 pig-tailed macaques in order to obtain a statistically valid protective neutralization endpoint titer in plasma. Using an in vitro assay which measures complete neutralization of the challenge SHIV, we correlated the titers of neutralizing antibodies in plasma at the time of virus inoculation (which ranged from 1:3 to 1:123) with the establishment of infection in virus-challenged animals. Ten of 15 monkeys in the present experiment were virus free as a result of neutralizing IgG administration as monitored by DNA PCR (peripheral blood mononuclear cells and lymph node cells), RNA PCR (plasma), virus isolation, and the transfer of lymph node cell suspensions (108 cells) plus 8 ml of whole blood from protected animals to naïve macaques. The titer of neutralizing antibodies in the plasma calculated to protect 99% of virus-challenged monkeys was 1:38.

UR - http://www.scopus.com/inward/record.url?scp=0036170921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036170921&partnerID=8YFLogxK

U2 - 10.1128/jvi.76.5.2123-2130.2002

DO - 10.1128/jvi.76.5.2123-2130.2002

M3 - Article

C2 - 11836389

AN - SCOPUS:0036170921

VL - 76

SP - 2123

EP - 2130

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 5

ER -